ArticleStem cells translational medicine2026
Exosome therapy for knee osteoarthritis: a network meta-analysis based on rat models.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo compare the therapeutic effects of exosomes from different cell sources and doses in rat knee osteoarthritis models using network meta-analysis, and to identify potential optimal strategies for preclinical optimization and clinical hypothesis generation.
methodsA systematic search of PubMed, Web of Science, Embase, and Scopus identified 27 eligible randomized controlled trials (456 rats). Traditional random-effects meta-analysis and frequentist network meta-analysis were conducted. Treatments were ranked using SUCRA values.
resultsA total of 27 studies were included, comprising 456 rats. Traditional meta-analysis revealed that exosome therapy significantly reduced joint cartilage histopathological damage (reduced OARSI score: SMD = -3.78, 95% CI: -4.76, -2.80), promoted type II collagen synthesis (SMD = 3.41, 95% CI: 1.87, 4.95), and suppressed the expression of the inflammatory cytokine IL-1β (SMD = -3.26, 95% CI: -4.08, -2.44). Network meta-analysis further indicated that under high-dose conditions (≥100 μg), exosomes derived from human amniotic fluid stem cells (hAFSCs-Exo) and human umbilical cord mesenchymal stem cells (hUCMSCs-Exo) ranked highest in relative efficacy for improving the OARSI score. hUCMSCs-Exo also demonstrated the most potent anti-inflammatory effect by reducing IL-1β. Overall, exosome therapy exhibited a dose-related trend in efficacy, with high-dose transplantation showing higher probabilistic SUCRA rankings across most outcome measures. However, assessment of publication bias revealed marked asymmetry; after trim-and-fill correction, the effect size for type II collagen expression decreased from SMD = 3.41 to 1.26, suggesting that the magnitude of the treatment effect may have been overestimated. This overestimation reduces the certainty of the observed treatment effects. Despite the presence of publication bias and methodological limitations, the main conclusions remained statistically robust after trim-and-fill correction.
conclusionCurrent evidence from rat models suggests that exosome therapy may substantially ameliorate the pathological progression of KOA, with exosomes derived from early developmental tissues, particularly hAFSCs-Exo and hUCMSCs-Exo, showing favorable chondroprotective and anti-inflammatory effects in the probabilistic ranking when administered at high doses. Nevertheless, the findings from publication bias and trim-and-fill analyses indicate that the existing effect sizes are likely overestimated. These results require confirmation in larger-scale, methodologically more rigorous preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.